| __timestamp | Amphastar Pharmaceuticals, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 1499100000 |
| Thursday, January 1, 2015 | 46974000 | 1923500000 |
| Friday, January 1, 2016 | 47298000 | 2351400000 |
| Sunday, January 1, 2017 | 50918000 | 2564000000 |
| Monday, January 1, 2018 | 58044000 | 2397300000 |
| Tuesday, January 1, 2019 | 63109000 | 2503400000 |
| Wednesday, January 1, 2020 | 65157000 | 3344600000 |
| Friday, January 1, 2021 | 68920000 | 4529200000 |
| Saturday, January 1, 2022 | 66592000 | 4179100000 |
| Sunday, January 1, 2023 | 80393000 | 4650100000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently outpaced Amphastar in SG&A spending, with an average annual expense of approximately $3 billion, compared to Amphastar's $59 million. Notably, Viatris's SG&A expenses surged by over 200% from 2014 to 2023, reflecting strategic investments and operational expansions. In contrast, Amphastar's expenses grew by about 99%, indicating a more conservative growth strategy. This financial insight highlights the contrasting business models and market strategies of these two pharmaceutical giants, offering a window into their operational priorities and market positioning.
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Viatris Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE